Open AccessSubtype‐specific cardiomyocytes for precision medicine: Where are we now?
Author(s) -
Zhao MingTao,
Shao NingYi,
Garg Vidu
Publication year - 2020
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.3178
Subject(s) - induced pluripotent stem cell , biology , embryonic stem cell , precision medicine , heart disease , disease , personalized medicine , phenotype , regenerative medicine , human induced pluripotent stem cells , heart development , stem cell , population , bioinformatics , medicine , neuroscience , genetics , gene , environmental health
Patient‐derived pluripotent stem cells (PSCs) have greatly transformed the current understanding of human heart development and cardiovascular disease. Cardiomyocytes derived from personalized PSCs are powerful tools for modeling heart disease and performing patient‐based cardiac toxicity testing. However, these PSC‐derived cardiomyocytes (PSC‐CMs) are a mixed population of atrial‐, ventricular‐, and pacemaker‐like cells in the dish, hindering the future of precision cardiovascular medicine. Recent insights gleaned from the developing heart have paved new avenues to refine subtype‐specific cardiomyocytes from patients with known pathogenic genetic variants and clinical phenotypes. Here, we discuss the recent progress on generating subtype‐specific (atrial, ventricular, and nodal) cardiomyocytes from the perspective of embryonic heart development and how human pluripotent stem cells will expand our current knowledge on molecular mechanisms of cardiovascular disease and the future of precision medicine.